For inquiries on this matter, please contact
- Mitsui & Co., Ltd.
Corporate Communications Division
Mitsui & Co., Ltd. ("Mitsui") (Head Office: Tokyo, Japan, President and CEO: Masami Iijima) will begin providing pharmaceutical companies and contract research organizations (CRO) with full outsourcing services for the logistics management of investigational drugs at the clinical development stage (new medicine development process). Mitsui expects to begin operations in the spring of 2011. The new service will enable pharmaceutical companies to outsource all activities related to investigational drug storage and delivery, which until now had to be managed internally, and concentrate on their core business of new drug development.
Pharmaceutical companies traditionally have been required by ministerial ordinance to provide investigational drug storage and delivery (investigational drug logistics) on their own. With the amendment of the Ministerial Ordinance on Standards for Implementation of Clinical Studies on Drugs (GCP Ministerial Ordinance) by the Ministry of Health, Labour and Welfare in April 2008, transportation companies and other third parties are now permitted to deliver investigational drugs to medical institutions. Because shippers must adhere to the strict controls and quality demanded for the administration of investigational drugs, however, the outsourcing of investigational drug logistics has in fact not progressed very far. In its investigational drug logistics management business, Mitsui will cooperate closely with pharmaceutical industry-related firms to offer logistics services that are based on the strict quality control level demanded by the pharmaceutical industry.
When offering this service, Mitsui will utilize the storage facility operated by Tokyo International Air Cargo Terminal Ltd. ("TIACT", a wholly-owned Mitsui subsidiary) in the new international freight terminal at Tokyo International Airport (Haneda), which opened for business on October 21. This is the first facility for investigational drugs to be established at an airport in Japan, and Mitsui has positioned Tokyo International Airport (Haneda) as its logistics hub for import and export of investigational drugs for clinical trials conducted in Japan and Asia. Mitsui will provide investigational drug logistics management services, including direct delivery, to medical institutions and other facilities throughout Japan and in other countries that conduct clinical trials.
As part of this business, Mitsui is working in cooperation with EPS Co., Ltd., Japan's leading CRO, and e-Trial Co., Ltd., a wholly-owned subsidiary of EPS, to develop the first investigational drug logistics management system in Japan. Mitsui will use this system to increase the efficiency of import/export shipment instructions and performance controls related to investigational drug logistics and to vastly improve logistics traceability (visibility and traceability).
Mitsui plans to support the promotion of clinical trials in Asia by Japan's pharmaceuticals companies in the future and will work to establish an investigational drug logistics network in Asia.
|Head Office||2-6-3, Haneda Airport, Ota-ku, Tokyo, Japan, 144-0041|
|Capital||JPY 2.4billion (as of October 1, 2010)|
|Employees||197 (as of October 1, 2010)|
|Business||·Establish, operate, and manage Tokyo International Air Cargo Terminal, and offer leasing services.
·Offer the following business services at the Tokyo International Air Cargo Terminal:
|Head Office||Tsuruya Bldg. 2-23 Shimomiyabi-cho, Shinjuku-ku, Tokyo, Japan, 162-0822|
|Employees||1301 (as of October 31, 2010)|
|Business||·Monitoring and other associated operations (IDMC)
·Clinical trials monitoring and data management
|Head Office||2-1 Shimomiyabi-cho, Shinjuku-ku, Tokyo, Japan, 162-0822|
|Employees||31 (as of October 31, 2010)|
|Business||Development and sales of clinical trial related software|
This press release includes forward-looking statements about Mitsui. These forward-looking statements are based on the current assumptions and beliefs of Mitsui in light of the information currently available to it, and involve known and unknown risks, uncertainties and other factors. Such risks, uncertainties and other factors may cause Mitsui's actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by these forward-looking statements. The risks, uncertainties and other factors referred to above include, but are not limited to, those contained in Mitsui's latest annual report on Form 20-F, which has been filed with the U.S. Securities and Exchange Commission.
This press release is published in order to publicly announce specific facts stated above, and does not constitute a solicitation of investments or any similar act inside or outside of Japan, regarding the shares, bonds or other securities issued by us.